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1. Introduction 
Several reports suggest hat enkephalins are neuro- 
modulators involved in the control of acute pain [I]. 
Their role in the control of chronic pain has been less 
extensively studied. Increased levels of Met-enkephalin 
(ME) were found in both dorsal and ventral halfs of 
the spinal cord of polyarthritic rats [2]. The origin of 
the elevated ME levels, either increased synthesis, 
decreased egradation or both is not known. Recent 
studies indicate that enkephalinase A (enkephalinase), 
amembrane-bound carboxydipeptidease [3], is selec- 
tively involved in the biological degradation of the enke- 
phalins [4,5 3. Hence changes in enkephalinase activity 
could play a role in the control of chronic pain. The 
finding that chronic morphine treatment has an effect 
on the enkephalinase activity, at least in the striatum, 
cortex and hypothalamus of mice, is consistent with 
this hypothesis [3,4]. To test a possible role of enke- 
phalinase in the control of chronic pain’we measured 
the ME-degrading activity of enkephalinase in different 
regions of the brain and spinal cord of chronic arthritic 
rats and control animals. 
The specific enkephalinase activity in the spinal 
cord was -40% of the activity in the striatum, the 
region presenting the highest activity in the central 
nervous system (CNS). The specific activity was higher 
in the dorsal half than in the anterior half of the spinal 
cord in correspondence with the known ME distribu- 
tion [2]. Chronic morphine treatment slightly increased 
the enkephalinase activity in several brain regions. 
However in chronic arthritic rats no difference in 
enkephalinase activity could be detected in any of the 
regions examined. 
2. Materials and methods 
Puromycin and p-chloromercuribenzoate (PCMB) 
were purchased from Aldrich, Tyr-Gly-Gly (TGG) 
from Serva, ME from UCB and [TJ+~,~-~H]ME (36 
Ci/mmol) from Radiochemical Centre (Amersham). 
Captopril was a gift from Squibb SA (Brussels). 
Porapak Q beads (loo-120 mesh) were obtained 
from Waters Associates and TLC Kieselgel60 plastic 
sheets (0.2 mm) from Merck. 
2.1. Arthritis induction 
The preparation and selection of arthritic rats 
were done at the Janssen Pharmaceutics Center 
(Beerse). Polyarthritis induction and housing condi- 
tions were as in [6]. 
2.2. Morphine implantation 
A morphine pellet (morphine-HC175 mg, chlor- 
butol l%, Mg-stearate 1% and lactose q.s. ad 100 mg) 
was implanted subcutaneously on the back of male 
Wistar rats (200 g body wt) under light ether anesthe- 
sia. Control rats received a placebo pellet. All opera- 
tions were carried out between 9:00 and 10:00 a.m. 
The absorption rate of morphine from the pellets was 
linear for at least 8 days (6.25%/day), as determined 
by absorption at 285 nm, after extraction of the mor- 
phine from the pellet with 0.1 N HCI. 
2.3. Brain and spinal cord dissection 
All animals were killed by decapitation between 
10:00 and 11 .OO a.m. and their brains and spinal 
cords were rapidly removed and placed on an ice-cold 
plate. The brain was dissected according to [7]. The 
lumbo-thoracal enlargement of the spinal cord was 
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cut in 1 mm slices on a glass plate cooled above Nz 
vapour and divided into a dorsal and ventral half. The 
cervical enlargement was kept intact. 
2 4. Preparation of a particulate fiat tion 
Tissues obtained from each rat were homogenized 
separately in 10 vol. (v/w) of 25 mM Tris-HCl buffer 
(pH 7.4 at 4°C) with a motor-driven Teflon pestle 
(2000 rev./min; Janke-Kunkel, Ika-Werk) in glass 
Potter homogenizers (Thomas AA) at 4°C. The homog 
enate was centrifuged at 10 000 X g for 20 min at 
4°C. The supernatant was discarded and the pellet 
resuspended in buffer and left for 1 h at 4°C. After a 
second centrifugation the final pellet was resuspended 
in 20-30 vol. (v/w) of buffer and kept frozen until 
use. Protein content of the particulate fractions was 
determined by the method [8]. 
2 5. Enkephalinase A assay 
Assays were performed in duplicate at 30°C for 
15 min in Eppendorf tubes, containing Tris-HCl 
buffer 25 mM (pH 7.4), PCMB 0.2 mM, puromycin 
0.2 n&I, [Tyr-‘HIME 10 nM and a sample of the par- 
ticulate fraction (containing 100-200 pg protein) in 
0.25 ml final vol. The reaction was started by adding 
[3H]ME and stopped with 0.1 ml 15%. After depro- 
teinisation the labeled metabolites were separated in 
duplicate by chromatography on Porapak Q beads 
columns (80 mg) as in [3,9]. Values were corrected 
by subtracting blanks being obtained by adding tri- 
chloroacetic acid before the ME solution. More than 
90% of the labeled metabolites, formed during the 
incubation, consisted of TGG as revealed by TLC 
(RF 0.36 in butanol:acetic acid:water, 4: 1: 1) (not 
shown). By cutting the entire TLC plate in fractions 
of 0.5 cm no other radioactive peakS than Tyr (RF 
0.5 l), TGG, ME (RF 0.75) and ME-oxide (RF 0.27) 
could be detected, excluding the action of enkephalin- 
ase B [lo] (not shown). The involvement of angio- 
tensin-converting enzyme in the formation of TGG 
can be ruled out by working with ME at < 100 nM 
[4]. Furthermore Captopril (SQ 14 225) a selective 
inhibitor of angiotensin-converting enzyme [ 111, 
added at 1O-8-1O-4 M did not decrease the formation 
of ME metabolites (not shown). 
The Tyr release during the assay is presumably 
caused by the contamination of the particulate frac- 
tion with nuclei. When a striatal membrane fraction, 
purified by using a discontinuous sucrose gradient 
[ 121, was tested in our assay only TGG was revealed. 
However, in the nuclear fraction a very high, partly 
inhibited by PCMB and puromycin, Tyr-releasing 
activity was found (not shown). 
3. Results and discussion 
3.1. Regional distribution of enkephalinase A 
In agreement with the known distribution of ME 
[ 131 and of opiate receptors [ 141 in rat brain, the 
highest enkephalinase A activity was found in the 
striatum. In the spinal cord the activity was only 
slightly lower than in the cortex or the brain stem 
and markedly higher in the dorsal than in the ventral 
part (table 1). This corresponds to the distribution of 
ME in the spinal cord, which is also higher in the 
dorsal part [2]. 
Only a few reports, which are difficult to compare 
Table 1 
Enkephalinase activity in various brain parts of arthritic and control rats at day 21 and 31 of the disease 
Brain area Day 21 Day 31 
Arthritis Control .Arthritis Control 
Cortex 145.68 f 8.04 (5) 149.44 * 16.35 (5) 132.64 f 12.11 (6) 128.06 f 11.63 (6) 
Striatum 352.68 f 12.52 (4) 362.92 ? 9.30 (5) 334.94 i 25.63 (6) 333.66 + 32.86 (6) 
Brainstem 192.88 ? 14.36 (5) 176.67 f 10.53 (5) 154.32 f 9.78 (6) 141.21 * 4.73 (6) 
Cervical 
spinal cord 143.58 + 4.86 (5) 142.14 ? 7.25 (5) 99.12 f 7.59 (6) 98.98 f 7.62 (5) 
Lumbo-thoracal 
spinal cord 
dorsal 148.25 f 10.67 (5) 141.53 * 12.32 (5) 121.93 f 11.13 (6) 124.43 f 4.68 (5) 
ventral 103.01 f 5.40 (5) 98.53 f 4.72 (5) 85.60 f 5.87 (6) 84.60 f 3.80 (5) 
Specific activity expressed as fmol ME degraded . mg protein-’ . min-‘; means f SEM (no. rats) 
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with our results, have described a regional distribu- 
tion of enkephalinase activity in rat brain. Data on 
the spinal cord are not available. In a first report [ 151 
the enzymatic activities were extremely low, probably 
due to proteolytic processes during the preparation of 
their particulate fraction and the absence of inhibitors 
in their assay. In a second report [ 161 very high values 
were obtained due to the purification of the enzyme 
source and the high enkephalin concentration in the 
assay. However, the activities in various brain struc- 
tures of the rat found here are very similar to those 
observed in mice and rats [4], if one takes into account 
the difference in incubation temperature. 
3.2. Effect of morphine and chronic pain on enke- 
phalinase A activity 
The possibility exists that manipulations of the 
enkephalinergic system(s) such as chronic morphine 
treatment or chronic pain, might alter the enkephalin- 
ase activity. In [3] enkephalinase activity increased 
after morphine pellet implantation in mice. These 
changes are also detectable in rats. Eight days after 
implantation of the morphine pellet an increase in 
the activity of the enkephalinase was observed in 
cortex, striatum and brainstem (not shown). It is not 
easy to relate these changes during chronic morphine 
administration to alterations in the enkephalin levels 
because of the lack of congruent data. They range 
from a 2-fold increase [ 171, no changes [ 181 or a 
decrease only after a short regimen implantation [ 191. 
To our knowledge only one report is available at 
the moment describing effects of chronic pain on the 
enkephalinergic system. In {2] no changes in ME 
levels were found in different brain areas of chronic 
arthritic rats at day 21 of the disease. We did not 
detect alterations of enkephalinase activity in cortex, 
striatum or brainstem (table 1). However increased 
ME levels in the spinal cord were observed [2]. 
Changes in enkephalinase activity in the cervical 
enlargement or in the dorsal or ventral halves of the 
lumbo-thoracal region could not be detected in our 
experiments at day 2 1. These observations are strength- 
enened by the fact that also in a later phase (day 3 1) 
no differences between arthritic and control rats were 
noticed (table 1). 
These results do not sustain the hypothesis that a 
decreased enkephalinase activity is responsible for the 
increase of ME levels observed in the spinal cord of 
chronic pain animals. Increased synthesis and/or 
78 
release of ME may be therefore more important 
mechanisms involved in the regulation of ME levels 
and the control of pain in the spinal cord. 
Acknowledgements 
We thank the Janssen Pharmaceutics Center for 
kindly providing the control and arthritic rats. This 
work was supported by grant OT/VII/34 from the 
Onderzoeksfonds K. U. Leuven. 
References 
111 
121 
131 
[41 
[51 
[61 
171 
181 
191 
[lOI 
[Ill 
[I21 
1131 
[I41 
[I51 
[I61 
[I71 
1181 
[I91 
Fields, H. L. and Basbaum, A. I. (1978) Annu. Rev. 
Physiol. 40, 217-248. 
Cesselin, F., Montastruc, J. L., Gras, C., Bourgoin, S. 
and Hamon, M. (1980) Brain Res. 191,289-293. 
Malfroy, B., Swerts, J. P., Guyon, A., Roques, B. P. 
and Schwartz, J. C. (1978) Nature 276,523-526. 
Schwartz, J. C., de la Baume, S., Malfroy, B., Patey, 
G., Perdrisot, R., Swerts, J. P., FourniB-Zaluski, M. C., 
Gacel, B. and Roques, B. P. (1980) in: Neural peptides 
and neuronal communication (Costa, E. and Trabucci, 
M. eds) pp. 219-235, Raven, New York. 
Snyder, S. H. (1980) Science 209, 976-983. 
De Castro Costa, M., De Sutter, P., Gybels, J. and Van 
Hees, J. (1981) Pain 10, 173-185. 
Gispen, W. H., Schotman, P. and De Kloet, E. R. (1972) 
Neuroendocrinology 9, 285-296. 
Lowry, 0. H., Rosebrough, N. J., Farr, A. L. and 
Randall, R. J. (1951) J. Biol. Chem. 193, 265-275. 
Vogel, Z. and Altstein, M. (1977) FEBS Lett. 80, 
332-336. 
Gorenstein, C. and Snyder, S. H. (1979) Life Sci. 25, 
2065-2070. 
Rubin, B., Laffan, R. J., Kotler, D. G., O’Keefe, E. H., 
Demaio, D. A. and Goldberg, M. E. (1968) J. Pharmacol. 
Exp. Therap. 204,271-280. 
Whittaker, V. P. (1965) Prog. Biophys. Mol. Biol. 15, 
39-96. 
Sar, M., Stumpf, W. E., Miller, R. J., Chang, K. J. and 
Cuatrecasas, P. (1978) J. Comp. Neural. 182, 17-37. 
Pert, C. B., Kuhar, M. J. and Snyder, S. H. (1976) Proc. 
Natl. Acad. Sci. USA 73, 3729-3733. 
Sullivan,C., Akil,H. and Barchas, J. D. (1979)Commun. 
Psychopharmacol. 2,525-531. 
Gorenstein, C. and Snyder, S. H. (1980) Proc. R. Sot. 
Lond. B 210,123-132. 
Simantov, R. and Snyder, S. H. (1976) Nature 262, 
505-507. 
Fratta,W., Yang, H.-Y. T., Hong, J. andCosta,E. (1977) 
Nature 268,452-453. 
Shani, J., Azov, R. and Weismann, B. A. (1979) Neu- 
rosci. Lett. 12. 319-322. 
